Physician profile
Abdallah Abboud
NPI 1912314824
$8,579.30
in general payments reported to CMS, 2019-2025
10 companies · $902 in 2025
The $902 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $36.32 · 2021: $1,570 · 2022: $5,677 · 2023: $276 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $625 · Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $624.80 |
| Food and Beverage | $552.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,436.74 | 2021-2023 | Da Vinci Surgical System |
| Abbott Laboratories | $901.72 | 2025 | Cardiomems |
| Ethicon INC. | $579.54 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $196.35 | 2021-2023 | Opsumit, Uptravi |
| Genentech USA, INC. | $138.38 | 2019-2021 | |
| Glaxosmithkline, LLC. | $108.86 | 2021-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $93.01 | 2020-2022 | |
| Chiesi USA, INC. | $65.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.04 | 2021 | |
| Grifols USA, LLC | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdallah Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.